Therma Bright's Venowave VW5 Secures Medicare Reimbursement Status Through HCPCS Code

Therma Bright Inc. has achieved a significant milestone in the compression therapy market with its Venowave VW5 device receiving a permanent Healthcare Common Procedure Coding System code from the U.S. Centers for Medicare and Medicaid Services. This designation makes the Venowave VW5 the only Medicare-approved, reimbursable mobile mechanical compression system available in the United States, providing patients with a lightweight and compact medical compression pump for managing post-operative recovery, pain, and swelling issues. The FDA-designated Durable Medical Equipment device offers a simple and comfortable treatment solution that now benefits from Medicare coverage.

The company has strengthened its market position through strategic distribution partnerships that leverage this reimbursement advantage. DME Authority, a national medical device distributor, has committed to a substantial inventory purchase including an initial order of 1,750 Venowave VW5 units, representing potential HCPCS code reimbursements of approximately $1.43 million. Another national distributor, Valor Medical, has placed an initial order for 100 units with potential for regular future purchases. These partnerships demonstrate the commercial viability of Therma Bright's compression therapy technology in the healthcare marketplace.

The global compression therapy market presents substantial growth opportunities for Therma Bright's expansion. According to Straits Research, the market was valued at $4.18 billion in 2024 and is projected to reach $6.72 billion by 2033, with a compound annual growth rate of 7.30%. This growth trajectory positions the company to capitalize on increasing demand for compression therapy solutions across healthcare settings. The permanent HCPCS code status provides Therma Bright with a competitive advantage in accessing this expanding market through established reimbursement pathways.

Beyond the Venowave VW5, Therma Bright is developing additional innovative medical technologies that complement its compression therapy offerings. The company is pursuing FDA classification for its acoustic AI Digital Cough Technology, a remote therapeutic monitoring solution designed to help healthcare providers and epidemiologists collect and analyze respiratory data. This diversification into digital health technologies demonstrates the company's commitment to expanding its product portfolio and addressing broader healthcare needs through technological innovation. These strategic developments position Therma Bright as an emerging player in the medical device technology sector with potential for continued expansion in both compression therapy and remote monitoring solutions.